

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland
www.lonza.com

Product News

Guidance for Environmental Infection Control for Ebola Virus

Basel, Switzerland, 21 October 2014 – Lonza is pleased to provide some guidance on the use of its portfolio of disinfectants and disinfectant cleaners as part of an infection control program for the Ebola virus.

On 1 August 2014, the U.S. Centers for Disease Control and Prevention (CDC) released guidance titled “Infection Prevention and Control Recommendations for Hospitalized Patients with Known or Suspected Ebola Hemorrhagic Fever in U.S. Hospitals”¹.

The CDC states in part: “Ebola viruses are transmitted through direct contact with blood or body fluids/substances (e.g., urine, feces, vomit) of an infected person with symptoms or through exposure to objects (such as needles) that have been contaminated with infected blood or body fluids. The role of the environment in transmission has not been established”.

It continues to say that, as part of the program of care of persons with probable or confirmed Ebola virus infections, hospitals are recommended to “Use a U.S. Environmental Protection Agency (EPA)-registered hospital disinfectant with a label claim for a non-enveloped virus (e.g., norovirus, rotavirus, adenovirus, poliovirus) to disinfect environmental surfaces in rooms of patients with suspected or confirmed Ebola virus infection”.

Separately, and in specific reference to “Environmental infection control”, the CDC has stated “Appropriate disinfectants for Ebola virus and other filoviruses include...hospital-grade quaternary ammonium...products”².

In addition, within Europe, the current EN 14885:2006 standard “Application of European Standards for Chemical Disinfectants and Antiseptics” stipulates that for a “virucidal” claim to be made for hard surface and instrument disinfectants, efficacy against poliovirus and adenovirus needs to be demonstrated using the EN 14476:2005 test protocol.

Lonza is a leading global manufacturer of disinfectants and disinfectant cleaners, many with supported label claims for viruses including those identified by U.S. CDC and within EN 14885:2006. Lonza offers for sale disinfectants with specific claims against target organisms as approved for the jurisdiction in which each product is sold.

¹ <http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-recommendations.html>

² <http://emergency.cdc.gov/han/han00364.asp>

Lonza Group Ltd
 Muenchensteinerstrasse 38
 4002 Basel, Switzerland
www.lonza.com

Product News

Available within Lonza’s U.S. portfolio are several product families that meet the CDC guidance to use products having efficacy against non-enveloped viruses including Bardac® 205M, Lonzagard® HWS, Lonzagard® R-82, Lonzagard® RCS and Lonzagard® Disinfectant Wipes. In Europe, Lonzagard™ DR-25aN Disinfectant Cleaner can make “virucidal” claims according to standards set by EN 14885:2006.

Lonza also offers HTH® Calcium Hypochlorite, a multi-purpose disinfectant and sanitizer. Chlorine products are widely recognized and recommended by international health authorities and used by non-governmental organizations. HTH® Calcium Hypochlorite has been registered for the sanitation of drinking and waste water and for the disinfection of hard surfaces, vehicles and containers, among other uses.

For further information, please find a list of your local regional contacts:

NAFTA	Todd Miller	todd.miller@lonza.com	+1 678 442 1001
EMEA	Anna Guest	anna.guest@lonza.com	+44 161 721 2023
Japan	Kazuaki Chiba Kazuhide Kawasaki	kazuaki.chiba@lonza.com kazuhide.kawasaki@lonza.com	+81 3 6264 0600
China	Hareton Liu	hareton.liu@lonza.com	+86 21 63403488 (Ext. 5871)
South East Asia	Nelson Tan	nelson.tan@lonza.com	+65 6521 4364
Latin America	Vinicius Bim	vinicius.bim@lonza.com	+55 11 4501 1226
India	Shilpa Pange	shilpa.pange@lonza.com	+91 22 4342 4017

About Lonza’s Hygiene Business

A key part of Lonza’s Consumer Care organization, the Hygiene business offers the broadest portfolio of registered actives, preservatives and formulations for use in disinfectants, sanitizers, and institutional and household cleaning products. This wide range of solutions are used to disinfect and sanitize schools, food processing plants, restaurants, grocery stores, hospitals, homes and more. More information can be found at www.lonzabiocides.com.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland
www.lonza.com

Product News

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza's stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.

Contact Information:

Lonza Inc.
Head of Global Marketing
Ernesto Lippert
Tel + 1 201 316 9434
ernesto.lippert@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.